Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04211675
Other study ID # STUDY00000476
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2022
Est. completion date December 2025

Study information

Verified date February 2024
Source Nationwide Children's Hospital
Contact Melinda Triplet, RN
Phone 614-722-6039
Email Melinda.Triplet@nationwidechildrens.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab. The phase 2 of the study will estimate the response to treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 31
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 29 Years
Eligibility Inclusion Criteria: - Less than 30 years of age when registered on the study. - Patients must have a histologic verification of neuroblastoma (NBL) or ganglioneuroblastoma or NBL cells in bone marrow with or without elevated urine catecholamines. - Life expectancy >2 months, AND one of the following: - Recurrent disease; or - First episode of progressive disease (new lesion, increase in size, previous negative bone marrow) during initial multi-drug, induction myelosuppressive therapy; or - Primary resistant/refractory disease (partial, mixed, stable response criteria met) after completing at least 4 cycles of induction multi-drug induction chemotherapy - One of the following: - Patients must have measurable or evaluable tumor defined as: a) Measurable tumor on MRI or CT obtained within 4 weeks prior to study entry; Measurable is defined as = 10mm in at least one dimension AND that has positive uptake on I-123 MIBG scan ("MIBG avid") or demonstrates increased FDG uptake on 18F-FDG PET-CT or PET-MRI ("PET-avid"); OR b) Evaluable tumor by I-123 MIBG scan within 4 weeks prior to study entry, defined as positive uptake at a minimum of one site; - Measurable or evaluable disease must represent recurrent disease after therapy completion or progressive disease on therapy or refractory disease during induction; - Patients with refractory disease that are not avid on MIBG scan and do not have increased FDG uptake on PET must have biopsy proven viable NBL; - New soft tissue sites that are MIBG avid or PET avid do not require biopsy as long as initial histologically-confirmed NBL diagnosis prior to current therapy - Patients must have progressed during or following completion of frontline therapy. Agents considered to be a part of frontline therapy would include chemotherapy, radiation therapy, autologous stem cell transplantation, retinoids, immunotherapy with anti GD2 agents, cellular therapies, or I-131 MIBG, and frontline therapy is defined as any combination of these agents defined in published regimens or current cooperative group clinical trials for the successful treatment of that cancer. Therapy may not have been received more recently than the timeframes defined below: - Myelosuppressive chemotherapy: At least 14 days since completion of myelosuppressive therapy - Biologic: At least 7 days since completion of therapy with non-myelosuppressive biologic or retinoid - Radiation: At least 4 weeks since completion of radiation to any site identified as a target lesion. Palliative radiation is allowed to sites not used to measure response - Stem Cell Transplant (SCT): At least 6 weeks after autologous stem cell transplant or stem cell infusions as long as hematologic criteria have been met - 131I-MIBG Therapy: At least 6 weeks after therapeutic MIBG treatment - Cellular therapies: At least 6 weeks after any cellular therapy treatment (e.g., prior NK, CAR-T therapy) Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible. Subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads are eligible. No treatment with irinotecan and/ or temozolomide within the last 6 months. - Adequate bone marrow function, defined as: - Peripheral absolute neutrophil count (ANC) =500/microL. Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days or short-acting myeloid growth factors (e.g., Neupogen) within 7 days of study entry. - Platelet count =50,000/microL (transfusion independent for at least 1 week) - Adequate renal function defined as: - Creatinine clearance or estimated radioisotope GFR =70 ml/min/1.73m2 or - Serum creatinine < 2x upper limit of normal (ULN) based on age/gender - Adequate liver function defined as: - Total bilirubin <1.5x ULN for age AND - SGPT (ALT) =5x ULN for age (or =225 U/L). For purpose of this study, the ULN for SGPT (ALT) is 45 U/L. - Adequate central nervous system function defined as: - Patients with seizure disorders may be enrolled if seizures are well controlled on anti-convulsants - CNS toxicity = Grade 2 - Adequate cardiac function defined as: - Shortening fraction of = 27% by ECHO OR - Ejection fraction = 50% by ECHO or gated radionuclide study - Adequate pulmonary function defined as: - No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry Exclusion Criteria: - Patients who are pregnant or breastfeeding - Patients with elevated catecholamines (>2x ULN) only. - Patients must not have received 0.5 mg/ kg/ day (prednisone equivalent) doses of systemic steroids for at least 7 days prior to enrollment. - Patients must not have received CYP3A4 inducer or inhibitor for at least 7 days prior to study enrollment. - Patients must not have been diagnosed with any other malignancy. - Patients must not have > Grade 2 diarrhea. - Patients must not have uncontrolled infection. - Patients with history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of anti-GD2 therapy. - Patients with a significant illness that is not covered by the exclusion criteria or that is expected to interfere with the action of study agents or to increase the severity of the toxicities experienced from the study treatment.

Study Design


Intervention

Biological:
Natural Killer Cells
NK cells dose 1x 108 cells/ kg on day 8 of each cycle
Drug:
Temozolomide
Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is <0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
Irinotecan
Irinotecan 50mg/m2/dose IV daily on Days 1-5
Dinutuximab
Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
Sargramostim
Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12

Locations

Country Name City State
United States Nationwide Children's Hospital Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Nationwide Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of the phenotype of expanded NK cells for neuroblastoma patients NK cell phenotypes will be measured by mass cytometry (unit of measure= % of nucleated cells) 36 months
Other Assessment of function of expanded NK cells for neuroblastoma patients NK cell functional potency will be measured as cytotoxicity by calcien- AM cytotoxicity assays (unit of measure= % of patietns with complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), or progressive disease (PD) with calculated 95% confidence intervals) 36 months
Other In vivo persistence of NK cells after adoptive transfer. To assess in vivo persistence of expanded NK cells after adoptive transfer by assessing NK cell number and phenotype in peripheral blood using mass cytometry. 36 months
Other Correlation of persistence of NK cells after adoptive transfer with clinical outcomes Clinical outcomes will be assessed by disease response using CT/MRI scans, I-123 metaiodobenzylguanidine (MIBG) scans, and bone marrow aspiration and biopsy 36 months
Primary NK cells safety and tolerability: Number of participants with treatment-related adverse events and toxicities Number of participants with treatment-related adverse events and toxicities as assessed by CTCAE v4.0 12 months
Primary Response to NK Cell treatment as determine by CT/MRI imaging To estimate the response to treatment, as determined by disease status evaluated using CT/MRI scans through the measuring tool RECIST. 24 months
Primary Response to NK Cell treatment as determine by MIBG scans imaging To estimate the response to treatment, as determined by disease status evaluated using MIBG scans through the Curie score system. 24 months
Primary Response to NK Cell treatment as determine by bone marrow aspiration To estimate the response to treatment, as determined by disease status evaluated using bone marrow aspiration and biopsy through H&E stain. RECIST. 24 months
Secondary Toxicity Definition of NK cells Toxicity will be graded using the CTCAE criteria, version 5.0. All grade 3+ toxicities will be reviewed for attribution. 36 months
See also
  Status Clinical Trial Phase
Completed NCT00939770 - Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213691 - Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05400603 - Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma Phase 1
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT05650749 - GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma Phase 1
Completed NCT02304458 - Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Phase 1/Phase 2
Completed NCT02095132 - Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04901702 - Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Phase 1/Phase 2
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03794349 - Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Phase 2
Recruiting NCT03155620 - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Phase 2
Active, not recruiting NCT04195555 - Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Withdrawn NCT04500548 - Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Phase 1
Suspended NCT04539366 - Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial Phase 1